Tyrphostin A9

Cat. No.:	HY-15511		
CAS No.:	10537-47-0		
Molecular Formula:	C ₁₈ H ₂₂ N ₂ O		
Molecular Weight:	282.38		
Target:	VEGFR; Influenza Virus; PDGFR		
Pathway:	Protein Tyrosine Kinase/RTK; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

SOLVENT & SOLUBILITY

In Vitro	0, 1	DMSO : 50 mg/mL (177.07 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (insoluble)					
	Solvent Mass Concentration	1 mg	5 mg	10 mg			
	Preparing Stock Solutions	1 mM	3.5413 mL	17.7066 mL	35.4133 mL		
		5 mM	0.7083 mL	3.5413 mL	7.0827 mL		
		10 mM	0.3541 mL	1.7707 mL	3.5413 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo		1. Add each solvent one by one: 0.5% CMC-Na/saline water Solubility: 5 mg/mL (17.71 mM); Suspended solution; Need ultrasonic					
		nt one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline mg/mL (8.85 mM); Clear solution					

BIOLOGICAL ACTIV	
BIOLOGICALACITY	
Description	Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti- influenza virus activities.
In Vitro	Tyrphostin A9 inhibited TNF-induced tyrosine phosphorylation of pyk2 without blocking the cells' bactericidal activity. Tyrphostin A9 is a PDGF receptor tyrosine kinase inhibitor (IC ₅₀ = 500 nM). Recent findings suggest that signaling via PDGF receptor tyrosine kinases is not necessary for the shift of the smooth muscle cells from a contractile to a synthetic phenotype. On the other hand these enzymes apparently carry out important functions in the control of intracellular membrane traffic and cell division.

Product Data Sheet

HO

N |||

[⊗]N



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Nat Cancer. 2022 Apr;3(4):453-470.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Park SJ, Park YJ, Shin JH, et al. A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation. Biochem Biophys Res Commun. 2011 May 13;408(3):465-70.

[2]. Richard F. Loeser, Christopher B. Forsyth, Allen M. Samarel et al. Fibronectin Fragment Activation of Proline-rich Tyrosine Kinase PYK2 Mediates Integrin Signals Regulating Collagenase-3 Expression by Human Chondrocytes through a Protein Kinase C-dependent Pathway. The Journal of Biological Chemistry, 2003, 278, 24577-24585.

[3]. Michele Fuortes, Maxine Melchior, Hyunsil Han, et al. Role of the tyrosine kinase pyk2 in the integrin-dependent activation of human neutrophils by TNF. J Clin Invest. 1999;104(3):327-335.

[4]. Johan Thyberg . Tyrphostin A9 and wortmannin perturb the Golgi complex and block proliferation of vascular smooth muscle cells. European Journal of Cell Biology.1998,76(1): 33-42

[5]. R Marhaba, F Mary, C Pelassy, et al. Tyrphostin A9 inhibits calcium release-dependent phosphorylations and calcium entry via calcium release-activated channel in Jurkat T cells. The Journal of Immunology. 1996,157 (4): 1468-1473

[6]. Kumar N, et al. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. J Virol. 2011 Mar;85(6):2818-2

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA